Reaction phenotyping: current industry efforts to identify enzymes responsible for metabolizing drug candidates.
about
Metabolic activation of clopidogrel: in vitro data provide conflicting evidence for the contributions of CYP2C19 and PON1How the Probability and Potential Clinical Significance of Pharmacokinetically Mediated Drug-Drug Interactions Are Assessed in Drug Development: Desvenlafaxine as an Example.Assays and applications in warfarin metabolism: what we know, how we know it and what we need to know.Software-aided cytochrome P450 reaction phenotyping and kinetic analysis in early drug discovery.Evaluation of a New Molecular Entity as a Victim of Metabolic Drug-Drug Interactions-an Industry Perspective.Improvement of the chemical inhibition phenotyping assay by cross-reactivity correction.Are there differences in the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2C9? A systematic investigation into inter-system extrapolation factors.A High-Throughput (HTS) Assay for Enzyme Reaction Phenotyping in Human Recombinant P450 Enzymes Using LC-MS/MS.In vitro metabolism of piperaquine is primarily mediated by CYP3A4.Incorporating population variability and susceptible subpopulations into dosimetry for high-throughput toxicity testing.In vitro metabolism of a novel antithrombotic compound, S002-333, and its enantiomers: quantitative cytochrome P450 phenotyping, metabolic profiling and enzyme kinetic studies.Clinical significance of CYP2C19 polymorphisms on the metabolism and pharmacokinetics of 11β-hydroxysteroid dehydrogenase type-1 inhibitor BMS-823778.Determination of metabolic profile of novel triethylamine containing thiophene S006-830 in rat, rabbit, dog and human liver microsomes.In vitro metabolism of the anti-inflammatory clerodane diterpenoid polyandric acid A and its hydrolysis product by human liver microsomes and recombinant cytochrome P450 and UDP-glucuronosyltransferase enzymes.
P2860
Q30840104-08466722-67B6-40B0-A494-F393749603A3Q36028281-7798C0E4-9A1E-4FCE-B563-EB47BEE09215Q37863679-AE99CC1E-7573-4DCB-85F6-452B9DF72757Q38675010-D341DB99-0769-430F-AC6B-8BB40ACCA370Q38800092-76576BBD-9F44-4D4D-85A3-3FFD4415447EQ39309971-56308484-C41B-402F-B5DC-0AD6DE287853Q39732707-CF343A4B-BF86-47D5-853E-7B180F316F6DQ40568343-6AA0B607-AD04-4DB7-A021-FE32F341FF5EQ41625322-EBEC9552-44F8-4BBE-A29B-44CC79D441CCQ42001999-6222948E-903C-49ED-B2CF-55F9D1201DCAQ43932208-3D37A4DD-A85F-449B-9657-7D897E8A6972Q48162596-46AE38D7-9E9F-43A5-AC60-67B9B7C0857BQ50559432-8EC74F2B-600D-4278-93D3-57837944B085Q51643121-8C364A30-DAD2-4DDE-A18A-A29BCA44135F
P2860
Reaction phenotyping: current industry efforts to identify enzymes responsible for metabolizing drug candidates.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Reaction phenotyping: current ...... metabolizing drug candidates.
@en
Reaction phenotyping: current ...... metabolizing drug candidates.
@nl
type
label
Reaction phenotyping: current ...... metabolizing drug candidates.
@en
Reaction phenotyping: current ...... metabolizing drug candidates.
@nl
prefLabel
Reaction phenotyping: current ...... metabolizing drug candidates.
@en
Reaction phenotyping: current ...... metabolizing drug candidates.
@nl
P2860
P1433
P1476
Reaction phenotyping: current ...... metabolizing drug candidates.
@en
P2093
Patrick J Brassil
Timothy W Harper
P2860
P2888
P304
P356
10.1208/S12248-008-9019-6
P407
P577
2008-04-05T00:00:00Z
P5875
P6179
1021263776